ITMI971190A0 - - Google Patents

Info

Publication number
ITMI971190A0
ITMI971190A0 ITMI971190A ITMI971190A ITMI971190A0 IT MI971190 A0 ITMI971190 A0 IT MI971190A0 IT MI971190 A ITMI971190 A IT MI971190A IT MI971190 A ITMI971190 A IT MI971190A IT MI971190 A0 ITMI971190 A0 IT MI971190A0
Authority
IT
Italy
Application number
ITMI971190A
Other languages
Italian (it)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ITMI971190A0 publication Critical patent/ITMI971190A0/it
Priority to IT97MI001190A priority Critical patent/IT1291372B1/it
Priority to EP98924313A priority patent/EP0983068B1/en
Priority to AT98924313T priority patent/ATE209492T1/de
Priority to CN98805120A priority patent/CN1255854A/zh
Priority to AU76546/98A priority patent/AU740475B2/en
Priority to CA002289847A priority patent/CA2289847A1/en
Priority to PCT/EP1998/002852 priority patent/WO1998052568A1/en
Priority to JP54991798A priority patent/JP2002502370A/ja
Priority to DE69802679T priority patent/DE69802679D1/de
Publication of ITMI971190A1 publication Critical patent/ITMI971190A1/it
Application granted granted Critical
Publication of IT1291372B1 publication Critical patent/IT1291372B1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IT97MI001190A 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie IT1291372B1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
AU76546/98A AU740475B2 (en) 1997-05-21 1998-05-14 The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances
AT98924313T ATE209492T1 (de) 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen
CN98805120A CN1255854A (zh) 1997-05-21 1998-05-14 1,2,4－三唑并[1,5－c]嘧啶杂环类似物在制备用于治疗心血管疾病的药物中的用途
EP98924313A EP0983068B1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
CA002289847A CA2289847A1 (en) 1997-05-21 1998-05-14 The use of 1,2,4-triazolo[1,5-c]pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
JP54991798A JP2002502370A (ja) 1997-05-21 1998-05-14 脳血管障害の処置に有用な薬剤の調製のための１，２，４−トリアゾロ［１，５−ｃ］ピリミジン複素環アナログの使用
DE69802679T DE69802679D1 (de) 1997-05-21 1998-05-14 Verwendung von 1,2,4-triazolo(1,5-c)pyrimidine heterocyclischen analogen zur herstellung von arzneimitteln zur behandlung von zerebrovascularen störungen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie

Publications (3)

Publication Number Publication Date
ITMI971190A0 true ITMI971190A0 (enExample) 1997-05-21
ITMI971190A1 ITMI971190A1 (it) 1998-11-21
IT1291372B1 IT1291372B1 (it) 1999-01-07

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie

Country Status (9)

Country Link
EP (1) EP0983068B1 (enExample)
JP (1) JP2002502370A (enExample)
CN (1) CN1255854A (enExample)
AT (1) ATE209492T1 (enExample)
AU (1) AU740475B2 (enExample)
CA (1) CA2289847A1 (enExample)
DE (1) DE69802679D1 (enExample)
IT (1) IT1291372B1 (enExample)
WO (1) WO1998052568A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132006A (en) * 2000-05-26 2007-09-28 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
EP1430898A4 (en) * 2001-09-28 2005-11-02 Kyowa Hakko Kogyo Kk Receptor antagonist
HUP0401777A3 (en) 2001-10-15 2008-06-30 Schering Corp 3h-[1,2,4]triazolo[5,1-i]purin-5-yl amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing the compounds
IL161573A0 (en) 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20030739A1 (es) 2001-11-30 2003-08-28 Schering Corp Antagonistas del receptor de adenosina a2a
US6916811B2 (en) 2001-11-30 2005-07-12 Schering Corporation Adenosine A2a receptor antagonists
AU2004233334B2 (en) 2003-04-23 2010-08-12 Merck Sharp & Dohme Corp. 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
EP1745047B1 (en) 2004-04-21 2010-03-24 Schering Corporation Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists
JP5084725B2 (ja) 2005-06-06 2012-11-28 武田薬品工業株式会社 有機化合物
CA2622741A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
WO2007143705A2 (en) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (en) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Organic compounds
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
JP5701608B2 (ja) 2007-12-06 2015-04-15 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN104370918A (zh) 2007-12-06 2015-02-25 武田药品工业株式会社 有机化合物
WO2009111449A1 (en) 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
JP2011528363A (ja) * 2008-07-16 2011-11-17 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アテローム性動脈硬化症の治療
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
MX2011005933A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
BRPI0922808A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
BRPI0922131A2 (pt) 2008-12-06 2015-08-18 Intracellular Therapies Inc Compostos orgânicos
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2590657A4 (en) 2010-05-31 2014-02-12 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
PL2970279T3 (pl) 2013-03-15 2021-05-31 Intra-Cellular Therapies, Inc. Związki organiczne
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
RU2711442C2 (ru) 2014-09-17 2020-01-17 Интра-Селлулар Терапиз, Инк. Соединения и способы
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
US10105349B2 (en) 2014-12-06 2018-10-23 Intra-Cellular Therapies, Inc. Organic compounds
MX371158B (es) 2014-12-06 2020-01-20 Intra Cellular Therapies Inc Compuestos inhibidores de pde2.
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3509589B1 (en) 2016-09-12 2021-11-17 Intra-Cellular Therapies, Inc. Novel uses
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH PROPERTIES OF A2A ANTAGONIST
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
JP7612672B2 (ja) 2019-09-03 2025-01-14 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規化合物
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Also Published As

Publication number Publication date
JP2002502370A (ja) 2002-01-22
CA2289847A1 (en) 1998-11-26
DE69802679D1 (de) 2002-01-10
ITMI971190A1 (it) 1998-11-21
EP0983068B1 (en) 2001-11-28
IT1291372B1 (it) 1999-01-07
EP0983068A1 (en) 2000-03-08
AU740475B2 (en) 2001-11-08
WO1998052568A1 (en) 1998-11-26
ATE209492T1 (de) 2001-12-15
CN1255854A (zh) 2000-06-07
AU7654698A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
ITMI971190A0 (enExample)
ITMI971039A0 (enExample)
IN183722B (enExample)
IN190855B (enExample)
ITME970012A0 (enExample)
ITRM970343A0 (enExample)
ITMI971308A0 (enExample)
ITCT970017A0 (enExample)
IN185768B (enExample)
CN3062610S (enExample)
CN3061573S (enExample)
CN3058138S (enExample)
CN3058088S (enExample)
CN3058057S (enExample)
CN3058025S (enExample)
CN3058000S (enExample)
CN3057997S (enExample)
CN3057977S (enExample)
CN3057976S (enExample)
CN3057730S (enExample)
CN3057614S (enExample)
CN3055179S (enExample)
CN3057613S (enExample)
CN3057436S (enExample)
CN3057322S (enExample)

Legal Events

Date Code Title Description
0001 Granted